Biotechs are still beaten up, especially the gene therapy disrupter stocks, so continuing to buy a little bit here and a little bit here of some of these stocks.
These are lottery stocks, they have few if any marketable products, but the idea is if they do come out with a block buster, well winner winner chicken dinner!!!
Adverum is into ocular gene therapy with several therapies in the pipeline with one to be late-stage clinical study.
Reason for the buy? Well a nice insider buy trade of $2.5 million in July which can often be a sign that something is in the making, or at least they have a lot of faith in the company moving forward.
Probably buy 100 shares here, that is a small under $700 position so if it goes to zero I am not hurting, but if it becomes a 10 or better bagger that is a nice hit. I mean various investors had the company above $200 for a while, so it is not unreasonable to get that type of move.
However the chances of that are low which is why we keep our risk low.
Anyways, good luck and I will touch base soon.
These are lottery stocks, they have few if any marketable products, but the idea is if they do come out with a block buster, well winner winner chicken dinner!!!
Adverum is into ocular gene therapy with several therapies in the pipeline with one to be late-stage clinical study.
Reason for the buy? Well a nice insider buy trade of $2.5 million in July which can often be a sign that something is in the making, or at least they have a lot of faith in the company moving forward.
Probably buy 100 shares here, that is a small under $700 position so if it goes to zero I am not hurting, but if it becomes a 10 or better bagger that is a nice hit. I mean various investors had the company above $200 for a while, so it is not unreasonable to get that type of move.
However the chances of that are low which is why we keep our risk low.
Anyways, good luck and I will touch base soon.
Exención de responsabilidad
La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.
Exención de responsabilidad
La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.